REG - Sareum Holdings PLC - Sareum Announces Two New Granted Patents

Sareum HoldingsAnnouncement

26/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230626:nRSZ8021Da&default-theme=true

RNS Number : 8021D  Sareum Holdings PLC  26 June 2023

 Sareum Holdings PLC

("Sareum" or the "Company")

Sareum announces two new granted patents, including first patent specifically
for SDC-1801

Cambridge, UK, 26 June 2023 - Sareum Holdings plc (AIM: SAR), a clinical-stage
biotechnology company developing next generation kinase inhibitors for
autoimmune disease and cancer, today announces that the first patent
specifically relating to SDC-1801, its lead TYK2/JAK1 kinase inhibitor, has
been granted in China. Further, a patent has been formally granted for
SDC-1802 and several analogues in the United States, extending the scope of
protection beyond immuno-oncology.

Dr John Reader, Sareum's Chief Scientific Officer, commented: "We're delighted
to have the first patent granted for SDC-1801, our lead development programme
which recently advanced into a Phase 1a clinical trial in Australia. We look
forward to being able to strengthen our intellectual property around this
asset in other territories in due course."

"Separately, we are really pleased to have extended the scope of patent
protection for SDC-1802 in the US. Although oncology remains the primary focus
of this asset, this bulwarks our intellectual property position and gives us
optionality to explore opportunities in other therapeutic areas."

SDC-1801 is a dual TYK2/JAK1 kinase inhibitor being developed as a potential
new therapeutic for a range of autoimmune diseases with an initial focus on
psoriasis, an autoimmune dermatological condition affecting more than 60
million adults worldwide, with a market size for potential treatments
estimated to be worth more than US$30 billion. Sareum recently announced that
it has begun dosing healthy subjects in a Phase 1a clinical trial for
SDC-1801, in Australia.

The China National Intellectual Property Administration (CNIPA) has officially
issued patent number CN113056456B, safeguarding SDC-1801 and medical
applications of it in treating inflammatory or immune disorders. This is the
first patent grant issued to Sareum for SDC-1801 in any territory. Patent
applications in Europe (EP3864009), the US (US2021387981) and other
territories are still under review.

SDC-1802 is a TYK2/JAK1 inhibitor being developed for cancer immunotherapy.
Sareum continues to work on the translational studies needed to support the
development of SDC-1802, defining the optimal cancer application prior to
completing toxicology and manufacturing studies.

The United States Patent and Trademark Office (USPTO) has formally granted
patent number US 11,673,870 B2 specifically covering the treatment of
autoimmune disorders with SDC-1802 and several analogues. While Sareum has
previously secured international patents providing comprehensive protection
for the compound SDC-1802, this patent extends its scope in the US beyond
immuno-oncology.

Further information on our patents can be found on our website at:
https://sareum.com/patents/

-Ends-

For further information, please contact:

 Sareum Holdings plc

 Tim Mitchell, CEO                                   01223 497700

 Lauren Williams, Head of Investor Relations         ir@sareum.co.uk

 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                         020 7409 3494

 Peel Hunt LLP (Joint Corporate Broker)

 James Steel / Oliver Duckworth                      020 7418 8900

 Hybridan LLP (Joint Corporate Broker)

 Claire Noyce                                        020 3764 2341

 Consilium Strategic Communications (Financial PR)

 Jessica Hodgson / Davide Salvi / Stella Lempidaki   020 3709 5700

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing
next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases and has entered
Phase 1a/b clinical development with an initial focus on psoriasis.

Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor
which it originally developed in collaboration with several Cancer Research
UK-related organisations. SRA737 has shown promising safety and efficacy in
two Phase 1/2 clinical trials.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential
application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market
of the London Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at www.sareum.com
(about%3Ablank)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAKKDADPDEFA